SCHEMBL19989210

SCHEMBL19989210

Cc1cc(S(=O)(=O)N2CCC[C@H]2CO)ccc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOX P28300 1/20 0.51
PIK3CD O00329 1/20 0.48
PIK3CG P48736 1/20 0.48
PLAU P00749 1/20 0.48
BRD4 O60885 1/20 0.48
BRD2 P25440 1/20 0.48
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTR7 P34969 7/20 0.46
HTR1A P08908 4/20 0.46
DRD2 P14416 4/20 0.46
HTR1D P28221 4/20 0.46
HTR1B P28222 4/20 0.46
DRD3 P35462 4/20 0.46
HTR6 P50406 2/20 0.46
CNR2 P34972 1/20 0.45
ABL1 P00519 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19989318 1.00 LOX (0.51) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL19989320 1.00 LOX (0.51) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL29859774 0.92 MEN1 (0.49) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL19989208 0.92 MEN1 (0.49) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL19989206 0.92 MEN1 (0.49) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL19989367 0.85 PLAU (0.56) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL19989366 0.85 PLAU (0.56) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL29859509 0.85 PLAU (0.56) LOXPIK3CDPIK3CGPLAUBRD4
SCHEMBL29859256 0.82 AKR1C3 (0.57) MEN1ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL1684459 0.81 BRD4 (0.57) LOXPLAUBRD4BRD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515913-B1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2022-05-11 EP disclosed
CN-109715629-B Aza-indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-04-12 CN disclosed
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2021-12-21 US disclosed
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-06-24 US disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2020-09-08 US disclosed
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-10-03 US disclosed
EP-3515913-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055551-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, TIMP3, ALPI LOX 1449/4885PIK3CD 1016/4885PIK3CG 1402/4885
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 LOX 1246/4885PIK3CD 1676/4885PIK3CG 1751/4885
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, TIMP3, ALPI LOX 1449/4885PIK3CD 1016/4885PIK3CG 1402/4885
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, ALPI, TIMP3 LOX 1424/4885PIK3CD 1071/4885PIK3CG 1427/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 LOX 1242/4885PIK3CD 1514/4885PIK3CG 1539/4885
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, ALPI, TIMP3 LOX 1424/4885PIK3CD 1071/4885PIK3CG 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.